An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
Cybin Inc. (NYSE American:CYBN) will report its financial results for Q2 fiscal 2021, ending September 30, 2021, on November 15, 2021. A conference call to discuss results will occur on the same day at 4:30 p.m. EST, hosted by CEO Doug Drysdale. The company is dedicated to developing safe and effective psychedelic therapeutics for mental health. Cybin operates in Canada, the U.S., the UK, and Ireland, leveraging advanced drug discovery and delivery systems.
Positive
Upcoming Q2 financial results announcement on November 15, 2021.
Focus on developing innovative psychedelic therapeutics for mental health issues.
Negative
None.
TORONTO--(BUSINESS WIRE)--
Cybin Inc. (NEO:CYBN) (NYSE American:CYBN) (“Cybin” or the “Company”), a biopharmaceutical company focused on progressing “Psychedelics to TherapeuticsTM” today announced that it will report financial results for its second quarter of fiscal 2021 ended September 30, 2021 on Monday, November 15, 2021.
A conference call will be held on the same day at 4:30 p.m. (EST) to discuss the results and recent business updates. The call will be hosted by Doug Drysdale, Cybin’s Chief Executive Officer. Mr. Drysdale and other members of the management team will be available to answer questions from participants following the prepared remarks.
CONFERENCE CALL DETAILS:
DATE:
Monday, November 15, 2021
TIME:
4:30 p.m. (EST)
DIAL-IN
1-844-200-6205 (U.S. toll free) or 1-833-950-0062 (Canada toll free)
An archived webcast will also be available on the Company’s Investor Relations site under the Events & Presentations page.
About Cybin
Cybin is a leading ethical biopharmaceutical company, working with a network of world-class partners and internationally recognized scientists, on a mission to create safe and effective therapeutics for patients to address a multitude of mental health issues. Headquartered in Canada and founded in 2019, Cybin is operational in the United States, United Kingdom and Ireland. The Company is focused on progressing Psychedelics to Therapeutics by engineering proprietary drug discovery platforms, innovative drug delivery systems, novel formulation approaches and treatment regimens for mental health disorders.
